Non-Invasive Prenatal Testing (NIPT) Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
- Report Code : 99S2263335
- Published On: Jan, 2021
- Category : Healthcare & Pharma
- Pages : 129
Get in-depth COVID-19 impact and recovery analysis on the Non Invasive Prenatal Testing Market
-
Summary
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Non-Invasive Prenatal Testing (NIPT) market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Non-Invasive Prenatal Testing (NIPT) market segmented into
Ultrasound Detection
Biochemical Screening Tests
Cell-Free Dna In Maternal Plasma Tests
Fetal Cells In Maternal Blood Tests
Others
Based on the end-use, the global Non-Invasive Prenatal Testing (NIPT) market classified into
Hospitals
Clinics
Research Laboratories
Based on geography, the global Non-Invasive Prenatal Testing (NIPT) market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
GE Healthcare
Koninklijke Philips
BGI Genomics
Illumina
Thermo Fisher Scientific
F. Hoffmann-La Roche
Pacific Biosciences Of California
Perkinelmer
Qiagen
Agilent Technologies
LifeCodexx
Berry Genomics
LifeLabs Genetics
Quest Diagnostics
Safembryo
Laboratory Corporation of America Holdings
Natera
Sequenom
Ariosa Diagnostics
CombiMatrix
-
With tables and figures helping analyze worldwide Non Invasive Prenatal Testing (NIPT) market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
1 RESEARCH SCOPE1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) INDUSTRY2.1 Summary about Non-Invasive Prenatal Testing (NIPT) Industry
2.2 Non-Invasive Prenatal Testing (NIPT) Market Trends
2.2.1 Non-Invasive Prenatal Testing (NIPT) Production & Consumption Trends
2.2.2 Non-Invasive Prenatal Testing (NIPT) Demand Structure Trends2.3 Non-Invasive Prenatal Testing (NIPT) Cost & Price
3 MARKET DYNAMICS3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Ultrasound Detection
4.2.2 Biochemical Screening Tests
4.2.3 Cell-Free Dna In Maternal Plasma Tests
4.2.4 Fetal Cells In Maternal Blood Tests
4.2.5 Others4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospitals
4.3.2 Clinics
4.3.3 Research Laboratories
5 NORTH AMERICA MARKET SEGMENT5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Ultrasound Detection
5.2.2 Biochemical Screening Tests
5.2.3 Cell-Free Dna In Maternal Plasma Tests
5.2.4 Fetal Cells In Maternal Blood Tests
5.2.5 Others5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Research Laboratories5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Ultrasound Detection
6.2.2 Biochemical Screening Tests
6.2.3 Cell-Free Dna In Maternal Plasma Tests
6.2.4 Fetal Cells In Maternal Blood Tests
6.2.5 Others6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Research Laboratories6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Ultrasound Detection
7.2.2 Biochemical Screening Tests
7.2.3 Cell-Free Dna In Maternal Plasma Tests
7.2.4 Fetal Cells In Maternal Blood Tests
7.2.5 Others7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospitals
7.3.2 Clinics
7.3.3 Research Laboratories7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Ultrasound Detection
8.2.2 Biochemical Screening Tests
8.2.3 Cell-Free Dna In Maternal Plasma Tests
8.2.4 Fetal Cells In Maternal Blood Tests
8.2.5 Others8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospitals
8.3.2 Clinics
8.3.3 Research Laboratories8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Ultrasound Detection
9.2.2 Biochemical Screening Tests
9.2.3 Cell-Free Dna In Maternal Plasma Tests
9.2.4 Fetal Cells In Maternal Blood Tests
9.2.5 Others9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Research Laboratories9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS10.1 Brief Introduction of Major Players
10.1.1 GE Healthcare
10.1.2 Koninklijke Philips
10.1.3 BGI Genomics
10.1.4 Illumina
10.1.5 Thermo Fisher Scientific
10.1.6 F. Hoffmann-La Roche
10.1.7 Pacific Biosciences Of California
10.1.8 Perkinelmer
10.1.9 Qiagen
10.1.10 Agilent Technologies
10.1.11 LifeCodexx
10.1.12 Berry Genomics
10.1.13 LifeLabs Genetics
10.1.14 Quest Diagnostics
10.1.15 Safembryo
10.1.16 Laboratory Corporation of America Holdings
10.1.17 Natera
10.1.18 Sequenom
10.1.19 Ariosa Diagnostics
10.1.20 CombiMatrix10.2 Non-Invasive Prenatal Testing (NIPT) Sales Date of Major Players (2017-2020e)
10.2.1 GE Healthcare
10.2.2 Koninklijke Philips
10.2.3 BGI Genomics
10.2.4 Illumina
10.2.5 Thermo Fisher Scientific
10.2.6 F. Hoffmann-La Roche
10.2.7 Pacific Biosciences Of California
10.2.8 Perkinelmer
10.2.9 Qiagen
10.2.10 Agilent Technologies
10.2.11 LifeCodexx
10.2.12 Berry Genomics
10.2.13 LifeLabs Genetics
10.2.14 Quest Diagnostics
10.2.15 Safembryo
10.2.16 Laboratory Corporation of America Holdings
10.2.17 Natera
10.2.18 Sequenom
10.2.19 Ariosa Diagnostics
10.2.20 CombiMatrix10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
-
The Non Invasive Prenatal Testing (NIPT) Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
- GE Healthcare
- Koninklijke Philips
- BGI Genomics
- Illumina
- Thermo Fisher Scientific
- F. Hoffmann-La Roche
- Pacific Biosciences Of California
- Perkinelmer
- Qiagen
- Agilent Technologies
- LifeCodexx
- Berry Genomics
- LifeLabs Genetics
- Quest Diagnostics
- Safembryo
- Laboratory Corporation of America Holdings
- Natera
- Sequenom
- Ariosa Diagnostics
- CombiMatrix
By Regions:
- North America [U.S., Canada, Mexico]
- Europe [Germany, UK, France, Italy, Rest of Europe]
- Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
- South America [Brazil, Argentina, Rest of Latin America]
- Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
By Type:
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free Dna In Maternal Plasma Tests
- Fetal Cells In Maternal Blood Tests
- Others
By Application:
- Hospitals
- Clinics
- Research Laboratories
